AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Gyre Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SDL5X7
5.85▼ 0.01 (-0.17%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
5.86
Day's Range
5.70 – 5.90
52-Week Range
5.44 – 9.16
Volume
151.5K
Avg Volume
167.8K
Share Statistics
Shares Outstanding
Employees
618
Exchange
XNAS
Listed
2023-10-31
Share count as of August 1, 2026

Gyre Therapeutics, Inc. Common Stock (GYRE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Gyre Therapeutics, Inc. Common Stock (GYRE)
What is Gyre Therapeutics, Inc. Common Stock's Market Cap?
Gyre Therapeutics, Inc. Common Stock's Market Cap is $652.3M, based on as-reported figures from SEC (XBRL) filings.
What is Gyre Therapeutics, Inc. Common Stock's Enterprise Value?
Gyre Therapeutics, Inc. Common Stock's Enterprise Value is $595.0M, based on as-reported figures from SEC (XBRL) filings.
What is Gyre Therapeutics, Inc. Common Stock's Price / Sales?
Gyre Therapeutics, Inc. Common Stock's Price / Sales is 5.9×, based on as-reported figures from SEC (XBRL) filings.
What is Gyre Therapeutics, Inc. Common Stock's EV / Revenue?
Gyre Therapeutics, Inc. Common Stock's EV / Revenue is 5.4×, based on as-reported figures from SEC (XBRL) filings.
What is Gyre Therapeutics, Inc. Common Stock's EV / EBITDA?
Gyre Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Gyre Therapeutics, Inc. Common Stock's Revenue (TTM)?
Gyre Therapeutics, Inc. Common Stock's Revenue (TTM) is $109.8M, based on as-reported figures from SEC (XBRL) filings.
What is Gyre Therapeutics, Inc. Common Stock's Net Income (TTM)?
Gyre Therapeutics, Inc. Common Stock's Net Income (TTM) is -$28.2M, based on as-reported figures from SEC (XBRL) filings.
What is Gyre Therapeutics, Inc. Common Stock's EBITDA?
Gyre Therapeutics, Inc. Common Stock's EBITDA is -$19.1M, based on as-reported figures from SEC (XBRL) filings.
What is Gyre Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Gyre Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.25, based on as-reported figures from SEC (XBRL) filings.
What is Gyre Therapeutics, Inc. Common Stock's EBITDA Margin?
Gyre Therapeutics, Inc. Common Stock's EBITDA Margin is -17.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · GYREAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues
YoY growth-2.1%+2.1%+33.4%+19.9%
Operating expenses:
Cost of revenues
Selling and marketing
Research and development—
General and administrative
Transaction costs——
Total operating expenses
% of revenue149.3%141.5%99.7%77.3%
(Loss) income from operations
% of revenue-49.3%-41.5%0.3%22.7%
Other (loss) income, net:
Interest income———
Other expense, net
Change in fair value of warrant liability
(Loss) Income before income taxes
Benefit (provision) for income taxes
Net (loss) income
Accretion of Cullgen redeemable convertible preferred stock———
Net loss attributable to noncontrolling interest
Net (loss) income attributable to common stockholders
Net (loss) income per share attributable to common stockholders, basic
Net (loss) income per share attributable to common stockholders, diluted